Drug Trial Radar · NCT05584670
A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Jun 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
542
Planned (sponsor's estimate)
Start
Nov 29, 2022
Primary completion
Jan 19, 2027
Study completion Jun 28, 2028
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- First posted
- Oct 18, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 1/2, open label, multiple cohort study to assess the safety and preliminary efficacy of SAR445877 as a monotherapy or in combination with other anticancer therapies for participants aged at least 18 years with advanced unresectable or metastatic solid tumors. The study will include 2 parts: A dose escalation Part 1: for finding the therapeutic dose(s) of SAR445877 in a monotherapy given every 2 weeks (Q2W) or weekly (QW) and in combination with other anticancer therapies when applicable. A multicohort dose expansion/dose optimization Part 2: for the assessment of safety and preliminary efficacy of SAR445877 in monotherapy and in combination with cetuximab or with next generation aCTLA4 (ADG126) or with bevacizumab. 2 recommended doses for expansion/optimization of SAR445877 identified from dose escalation part 1 will be tested in different indications in monotherapy and in combination with other anticancer therapies as applicable. Approximately 542 participants will be exposed to the study intervention: * approximately 123 participants in part 1, * up to 410 participants in expansion/dose optimization part (part 2) * and up to 9 participants in Japan cohort F.
Conditions
- Solid Tumor
Interventions
SAR445877Drug
Concentrate for solution for infusion
CetuximabDrug
Solution for infusion
ADG126Drug
Solution for infusion
BevacizumabDrug
Solution for infusion
NivolumabDrug
Solution for infusion
IpilimumabDrug
Solution for infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose escalation part 1A, 1C and Japan Cohort F: Presence of dose-limiting toxicities (DLTs) in Cycles 1 and 2Time frame: Cycles 1 & 2 - 14 days per cycle
- Dose escalation part 1B: Presence of dose-limiting toxicities (DLTs) in Cycle 1 to 3 in part BTime frame: Cycle 1 to 3 -14 days per cycle
- Dose escalation and Japan Cohort F: Percentage of participants experiencing treatment-emergent adverse events (TEAEs)Time frame: The time from the first dose of study interventions up to 30 days after last dose of study interventions
- Dose expansion/optimization: Objective response rate (ORR)Time frame: From baseline to the end of dose expansion/optimization (up to 2 years)
Locations
22 sites in 6 countries. Site status is shown where the registry gives one.
Christiana Care Health System - Newark- Site Number : 8400011
Newark, Delaware · Recruiting
University of Iowa- Site Number : 8400014
Iowa City, Iowa · Recruiting
The University of Kansas Cancer Center - Westwood- Site Number : 8400008
Westwood, Kansas · Recruiting
Karmanos Cancer Institute - Detroit- Site Number : 8400006
Detroit, Michigan · Recruiting
John Theurer Cancer Center- Site Number : 8400001
Hackensack, New Jersey · Recruiting
NYU Langone Medical Center- Site Number : 8400013
New York, New York · Recruiting
Rhode Island Hospital - Providence - Eddy Street- Site Number : 8400004
Providence, Rhode Island · Recruiting
The University of Texas MD Anderson Cancer Center- Site Number : 8400005
Houston, Texas · Recruiting
Fred Hutchinson Cancer Center- Site Number : 8400010
Seattle, Washington · Recruiting
Fundacion Arturo Lopez Perez (FALP) - Providencia - Jose Manuel Infante 805_Investigational Site Number : 1520007
Providencia, Chile · Recruiting
Servicios Médicos URUMED SpA_Investigational Site Number : 1520002
Rancagua, General Bernardo O'Higgins, Chile · Recruiting
BIOCINETIC Ltda_Investigational Site Number : 1520008
Santiago, Reg Metropolitana de Santiago, Chile · Recruiting
Centro de Investigacion Clinica Bradford Hill_Investigational Site Number : 1520004
Santiago, Reg Metropolitana de Santiago, Chile · Recruiting
Sheba Medical Center - PPDS_Investigational Site Number : 3760003
Ramat Gan, Israel · Recruiting
Tel Aviv Sourasky Medical Center Ichilov - PPDS_Investigational Site Number : 3760001
Tel Aviv, Israel · Recruiting
Shamir Medical Center_Investigational Site Number : 3760004
Tzrifin, Israel · Recruiting
Hadassah Medical Center - PPDS_Investigational Site Number : 3760005
Jerusalem, Jerusalem, Israel · Recruiting
Investigational Site Number : 3920001
Kashiwa, Chiba, Japan · Active not recruiting
Het Nederlands Kanker Instituut Antoni Van Leeuwenhoek Ziekenhuis_Investigational Site Number : 5280001
Amsterdam, North Holland, Netherlands · Recruiting
Erasmus MC_Investigational Site Number : 5280003
Rotterdam, South Holland, Netherlands · Recruiting
START MADRID_Hospital Universitario HM Sanchinarro - CIOCC_Investigational Site Number : 7240005
Madrid, Spain · Recruiting
Instituto de Investigacion Oncologica Vall d'Hebron (VHIO) - EPON_Investigational Site Number : 7240007
Barcelona, Barcelona [Barcelona], Spain · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.